U.S. Markets open in 8 hrs 13 mins

Today’s Research Reports on Trending Tickers: Aurinia Pharmaceuticals Inc. and INSYS Therapeutics, Inc.

NEW YORK, NY / ACCESSWIRE / January 5, 2018 / On Thursday, all three major indexes rose for the third consecutive day, with the Dow Jones crossing the 25,000 plateau for the first time ever. The Dow Jones Industrial Average gained 0.61 percent to close at 25,075.13, while the S&P 500 Index increased 0.40 percent to close at 2,723.99. The Nasdaq Composite Index rose 0.18 percent to close at 7,077.91. This marked the first time the S&P 500 and the Nasdaq have closed at record highs for three consecutive trading sessions to begin the new year since 1964 and 1999, respectively.

“Momentum was the single-biggest factor driving prices in 2017, and that remains the case so far this year. Valuations are stretched, no question, based on historical standards, but they're OK relative to bond yields and inflation, which means we're not overly concerned about them at this juncture,” said Michael Mullaney, director of global market research at Boston Partners, according to MarketWatch.

RDI Initiates Coverage on:

Aurinia Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=AUPH

INSYS Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=INSY

Aurinia Pharmaceuticals stock jumped 5.42% Thursday, to close the day at $5.25. The stock recorded a trading volume of 1,454,430 shares, which was above its three months average volume of 1,205,658 shares. In the last year, Aurinia Pharmaceuticals shares have traded in a range of 2.11 - 10.54. The share price has gained 148.82% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.96 is below its 200-day moving average of $5.94. Shares of Aurinia Pharmaceuticals have gained roughly 1.55 percent in the past month and are up 15.89 percent year-to-date.

Access RDI's Aurinia Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AUPH

On Thursday, shares of INSYS Therapeutics, Inc. recorded a trading volume of 6,904,773 shares, which was above the three months average volume of 1,202,703 shares. The stock ended the day 26.31% lower at 9.86. The share price has gained 140.49% from its 52-week low with a 52-week trading range of 4.10 - 15.02.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $6.52 is below its 200-day moving average of $8.79. Shares of INSYS Therapeutics, Inc. have gained roughly 89.25 percent in the past month and are up 2.49 percent year-to-date.

Access RDI's INSYS Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=INSY

Our Actionable Research on Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and INSYS Therapeutics, Inc. (NASDAQ:INSY) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com